The Week in Review: Tigermed and Shuangcheng Pharma Complete IPOs
Published: Aug 21, 2012
August 18, 2012 -- Hangzhou Tigermed Consulting, a clinical-stage CRO, staged an $80 million IPO on Shenzhen’s ChiNext exchange; Hainan Shuangcheng Pharma made its public company debut on the Shenzhen main board, raising $94 million; two China medical research organizations will work with the National University of Ireland Galway to develop polymer delivery systems for chemotherapy; Cipla, an Indian generic drug maker, pulled $72 million out of its 49% investment in China’s Desano Holdings, and then put between $20 million and $25 million into each of three Desano subsidiaries; Medtronic is in M&A talks with several China medical device companies; WuXi PharmaTech announced its Q2 revenues climbed 29% to $130 million, a record; and 3SBio filed an IND application with the SFDA to begin clinical trials of a monoclonal antibody drug candidate discovered by Apexigen of San Francisco. More details….
Stock Symbols: (SHE: 300347) (SHE: 002693) (BSE: 500087) (NYSE: MDT) (NYSE: WX) (NSDQ: SSRX)